Laguna Pharmaceuticals Obtains $30,000,000 Series B Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c5759abd-53e4-4efb-b064-b9174296c948
Date
2/17/2015
Company Name
Laguna Pharmaceuticals
Mailing Address
Undisclosed La Jolla, CA 92130 USA
Company Description
Laguna Pharmaceuticals, formerly known as ChanRx, is a biopharmaceutical company advancing vanoxerine for treatment of atrial fibrillation and atrial flutter.
Website
http://www.lagunarx.com
Transaction Type
Venture Equity
Transaction Amount
$30,000,000
Transaction Round
Series B
Proceeds Purposes
Laguna Pharmaceuticals plans to use the proceeds to progress Phase 3 clinical development of its lead compound, vanoxerine, a therapeutic drug candidate for the treatment of atrial fibrillation (AF) and atrial flutter (AFL).
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor